Humacyte is a biotechnology company that develops and manufactures acellular tissue-engineered blood vessels (ATEVs) for regenerative medicine applications using a proprietary platform that grows bioengineered human tissue on biodegradable scaffolds and then removes immune-triggering cells to create off-the-shelf, universally implantable vascular conduits. The company's lead product is designed for vascular trauma, hemodialysis access, and peripheral artery disease, with a pipeline extending to coronary bypass grafting and other organ engineering applications. Humacyte generates revenue by selling these bioengineered vessels directly in the U.S. to trauma centers and dialysis facilities, while licensing commercialization rights to partners outside the U.S. and European Union; reimbursement is pursued through healthcare payers and governmental coverage programs based on the cost-effectiveness profile of the products relative to alternative treatments.